Author: Ravi Shankar

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) will release third quarter 2026 financial and operating results on Wednesday, October 28, 2026 after the close of the Toronto Stock Exchange (“TSX”). The Company will host a conference call and webcast to discuss the results on Thursday, October 29, 2026 at 9:00 am (ET).

Conference call and webcast details:
Toll-free North America: 1-800-715-9871
International: +1-646-307-1963
Conference ID: 8111752
Webcast: Direct link or on our website

A replay of the webcast will be available on the First Quantum website.

About First Quantum

First Quantum is engaged in the production of copper, nickel and gold, and related activities including exploration and development. The Company has operating mines located in Zambia and Mauritania. The Company’s Cobre Panamá mine was placed into a phase of Preservation and Safe Management in November 2023. The Company’s Ravensthorpe mine was placed into a care and maintenance process in May 2024. The Company is progressing the Taca Taca copper-gold-molybdenum project in Argentina and is exploring the La Granja and Haquira copper deposits in Peru.

For further information, visit our website at www.first-quantum.com or contact:

Investor Relations:
Bonita To, Director, Investor Relations & Capital Markets
(416) 361-6400
Toll-free: 1 (888) 688-6577
E-Mail: info@fqml.com

Media Relations:
James Devas, Manager, Corporate Affairs
+44 207 291 6630
E-Mail: james.devas@fqml.com

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Halcones Precious Metals Corp. (TSXV: HPM) (the “Company” or “Halcones”), further to its press release dated October 20, 2025, announces that Minera Los Halcones SpA (“Minera Halcones”), Halcones’ wholly-owned subsidiary, has been advised that the independent Court-appointed expert has submitted her compensation valuation report to the Civil Court of Taltal, Chile (the “Court”) in connection with the application before the Court to obtain surface rights access to the Polaris project (“Polaris” or the “Project”).

Halcones, representing Austral Exploraciones SpA (“Austral”), the owner of the Polaris mining concessions that have been optioned by the Company pursuant to a binding option agreement with Austral, continues to pursue obtaining an easement for surface access to diamond drill the Project through the Chilean legal system before the Court. The legal proceedings were initiated on October 30, 2025, and over the last few months all the Court’s requests for additional information have been satisfied. The Court has been asked to rule on the surface access easement. Under Chilean law, similar to many jurisdictions including Canada, mineral rights, which are owned by the state, have preference over surface rights and there is a well-established process that will be followed to achieve access and arrange compensation for the surface rights holder. The Company continues to seek a negotiated agreement with the surface rights holders while the legal process proceeds but intends to pursue all legal avenues to obtain Polaris surface access as soon as possible.

With the submission of the expert report, the evidentiary stage of the proceeding is now substantially complete, and the matter is moving toward resolution by the Court. The expert’s mandate was to quantify the compensation payable, and the report sets out the amounts of compensation payable to the surface rights owners.

Although there is no set timeline for a decision by the Court, the fact that there is now no other pending procedures necessary is a positive sign and the Company looks forward to a decision from the Court shortly.

About Halcones Precious Metals Corp.

Halcones is focused on exploring for and developing gold-silver projects in Chile. The Company has a team with a strong background of exploration success in the region.

For further information, please contact:

Vincent Chen, CPA
Investor Relations
Vincent.chen@halconespreciousmetals.com
www.halconespreciousmetals.com
647-276-0540

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, amendments to the Polaris Option Agreement, surface rights access to the Polaris project, a ruling by the Court, the timing and outcome of the easement proceeding and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward- looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Halcones, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; the actual results of current exploration activities; risks associated with operation in foreign jurisdictions; ability to successfully integrate the purchased properties; foreign operations risks; and other risks inherent in the mining industry. Although Halcones has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Halcones does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACs

BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs).

Nurix entered into the collaboration with Seagen Inc., now part of Pfizer, in September 2023. Under the terms of the agreement, Nurix received an upfront payment of $60 million and became eligible to receive up to $3.4 billion in potential research, development, regulatory and commercial milestone payments across multiple programs, as well as mid-single-digit to low-double-digit percentage tiered royalties on future product sales. Nurix also retains an option for U.S. profit sharing and co-promotion on up to two products arising from the collaboration. In connection with today’s announcement, Nurix will receive a $7 million milestone payment from Pfizer, which will bring the total amount received under this agreement to $82 million.

About Degrader Antibody Conjugates (DACs)
DACs are an emerging therapeutic modality designed to combine the cell and tissue selectivity of antibodies with the catalytic mechanism of targeted protein degraders. Unlike traditional antibody-drug conjugates (ADCs), which typically deliver cytotoxic payloads to antigen-expressing cells, DACs deliver targeted protein degraders designed to eliminate specific disease-driving proteins. This approach has the potential to provide multiple layers of selectivity based on cell-surface antigen expression, the intracellular protein target and E3 ligase expression.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s expectations for its collaboration with Pfizer; the potential benefits of Nurix’s collaboration with Pfizer; the potential benefits of degrader antibody conjugates; and the potential achievement of milestone, royalty and license payments under the Nurix-Pfizer collaboration. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes such expectations and assumptions are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the ability of each party to perform its obligations under the Nurix-Pfizer collaboration; (ii) whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Nurix-Pfizer collaboration; (iii) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development; (iv) whether Nurix will be able to fund development activities and achieve development goals, including those under the Nurix-Pfizer collaboration; (v) risks and uncertainties relating to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media and Investors
Kris Fortner
Nurix Therapeutics, Inc.
ir@nurixtx.com

Exercise of existing purchase option has been completed in conjunction with growing commercialization opportunities

MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces that is has completed the acquisition of a 50% ownership interest in HPQ Silica Polvere Inc. (“HSPI”). HSPI’s primary line of business is commercialization of the Fumed Silica Reactor (the “FSR”), a proprietary technology originally developed and built by PyroGenesis to convert quartz (SiO₂) into fumed silica in a single and eco-friendly step while eliminating the use of harmful chemicals generated by conventional methods.

Fumed silica is a widely used industrial material found in thousands of products. If commercially successful, the FSR could significantly advance the reshoring of fumed silica production from China-based producers to domestic facilities by enabling localized, modular, and on-demand fumed silica production near end users’ manufacturing facilities across North America.

Before completion of the acquisition, HSPI was a wholly-owned subsidiary of HPQ Silicon Inc. (“HPQ”). Since 2021 [press release dated July 6, 2021], PyroGenesis has held: (i) a 10% annual royalty on HSPI’s sales (the “Royalty”) of fumed silica, (ii) the rights, under an agreement with HPQ, to convert the Royalty into a 50% interest in HSPI, and (iii) an exclusive arrangement to be the sole supplier of equipment relating to any commercialization of the FSR.

PyroGenesis previously announced its intention to convert the Royalty into an ownership interest [press release dated May 30, 2024]. With the completion of the acquisition announced today, the Royalty has been converted into a 50% ownership interest in HSPI. PyroGenesis also retains its exclusive arrangement to serve as the sole supplier of equipment relating to any commercialization of the FSR.

“The market opportunities for the fumed silica reactor technology continue to grow, and we now have partnership interest across multiple sectors and geographies,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “Completing the 50% ownership agreement in HSPI was a necessary step to properly engage with additional clients around the world who have recently expressed interest in the FSR technology and production capabilities.”

Image 1: containers of fumed silica produced by PyroGenesis’ fumed silica reactor.

UPDATE ON COMMERCIAL DEVELOPMENTS

In August, the Company provided an update on its fumed silica business line [press release August 17, 2026], including its commercial potential and the status of recent customer interest, specifically regarding four separate entities. Since that release, the following developments have occurred:

1. The first entity is a Global Manufacturer of fumed silica, who previously had signed a letter of intent [announced July 9, 2024] that outlined the basis of collaboration between the entity and PyroGenesis and Polvere during the pilot scale phase of the FSR development. As per the signed MOU, the goal of the pilot scale phase was to validate the ability of the FSR to produce low-cost, low carbon material acceptable to the manufacturer’s specifications.

   The Company reported previously that following the successful completion of the fumed silica reactor pilot program objectives, the parties are evaluating potential frameworks for the next phase of their collaboration, including opportunities to support the commercial deployment of the FSR.

   The Company reports today that discussions have resumed. An additional meeting is scheduled for the week of September 28 to discuss further details regarding the go-forward framework.

2. The second entity is a potential Joint Venture Partner, with whom the Company reported previously the potential formation of a joint venture (the “JV”) for the purpose of operating a 1,000 tonne per year fumed silica production plant (with the fumed silica produced to be used by the Joint Venture Partner in a new application) and with an expectation that there would be a need for a series of additional fumed silica plants of the same or larger size. It was indicated that the JV is contingent upon the successful negotiation and execution of one or more definitive agreements pertaining to the JV and related obligations by the parties thereto.

   The Company reported previously that discussions were stalled, and that PyroGenesis had proposed a compromise position for which a response had yet to be received at the time of the August release.

   The Company reports today that discussions recently resumed with in-person meetings. A team from PyroGenesis recently returned from one of the client’s U.S. facilities, where meetings were held to discuss proposed changes. The proposed changes were favorably received by both sides and negotiations have actively resumed.

3. The third entity is a potential Asian customer that uses fumed silica in their end product, and who wishes to collaborate in establishing a production facility in North America to better address the local market, with discussions involving large-scale bulk supply of fumed silica and/or local fumed silica production plants. Additionally, the Client had indicated that demand could require several 10,000 tonnes per year FSR systems.

   The Company reports today that discussions with this entity continue, with the entity recently requesting a meeting at PyroGenesis’ headquarters to accelerate the process.

4. (iv) The fourth entity, an existing PyroGenesis customer with significant business operations in the Middle East, indicated a desire for the potential construction of a local fumed silica production plant to serve the Middle Eastern market. Additionally, it was indicated that negotiations planned for the 2nd half of 2026 will help determine the scale of the agreement, potentially focusing on a 10,000 tonnes per year production plant.

   The Company reports today that negotiations are still planned for the 2^nd half of 2026.

INDUSTRY AND MARKET CONTEXT

• Fumed silica is one of the most widely used industrial materials and can be found in thousands of consumers and industrial products, including cosmetics, toothpaste, pet litter, powdered food, milkshakes, instant coffee, pharmaceuticals, agriculture, adhesives, paints, inks, photocopy toner, sealants, fiber optic cables, thermal insulation, construction materials, and batteries, to name a few. It is often used in these products as a thickening/anti-caking agent, used to stabilize and improve the texture, consistency, and flow of the end-product.
• The global fumed silica market is projected to surpass US$2.57 billion by 2034, driven by growing demand in the coatings, sealants, automotive, and lithium-ion battery sectors. ¹
• PyroGenesis was originally engaged to develop and build the FSR pilot plant for HPQ Polvere Inc., a subsidiary of HPQ Silicon Inc.
• PyroGenesis now has a 50% ownership of HSPI (the FSR rights-holder) and exclusive arrangement to be the sole supplier of equipment relating to any FSR commercialization.

About the Fumed Silica Reactor

PyroGenesis is the exclusive supplier of plasma-based technology that uses quartz (SiO₂) as a raw material to produce commercial-grade fumed silica in a single and eco-friendly process while eliminating the use of harmful chemicals generated by certain conventional methods. The FSR requires no additional processes to develop to prepare feedstock, and no intermediary toxic chemical-based processing. The FSR can produce fumed silica from quartz at one physical location. When compared to some multi-step, traditional processing methods, the expected benefits of the FSR process can generally be summarized as follows:

1. Lower capital costs.
2. Lower operating costs.
3. Reduction of CO₂ emissions.
4. Reduction in energy footprint.
5. Elimination of purchase and storage requirements for hazardous chemicals.
6. Simplified logistics/shortened production chain due to the single location, single system, single phase process, and the elimination of feedstock ingredient handling, storage, preparation/transformation, and transportation.
7. Safer production environment due to absence of dangerous, toxic, or explosive chemicals.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact ir@pyrogenesis.com or visit http://www.pyrogenesis.com

_____________________________
¹ https://finance.yahoo.com/news/fumed-silica-market-reach-usd-143000439.html

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/210ecdfb-249f-4456-9e77-777a0aac39f8

Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors

WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company’s Board of Directors, effective October 14, 2026. Mr. Daly has three decades of leadership experience in large and small biopharmaceutical companies, with a focus on commercial and operating roles.

“I am very pleased to welcome Rich to the Aquestive Board,” said Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics. “Rich brings extensive experience supporting commercial launches and building biopharmaceutical commercial organizations, including through senior leadership roles at AstraZeneca, Takeda, and Catalyst. His commercial and operating perspective will be valuable and add to the board’s existing commercial experience as we continue our preparations for the potential launch of Anaphylm, if approved by the FDA.”

Following Mr. Daly’s appointment, the Board will consist of eight directors, seven of whom the Board has determined are independent under applicable Nasdaq listing standards.

“We are delighted to welcome Rich to the Board of Directors,” said Gregory B. Brown, M.D., Chairman of the Board of Aquestive. “Rich has built commercial organizations from their earliest stages, led launches of both primary care and specialty therapies, and guided companies through significant acquisitions, integrations, and capital formation. His experience as a chief executive, together with his public company board service, will be a valuable addition to the Company’s board as the Company moves into its next phase.”

Mr. Daly said, “I am pleased to be joining the Aquestive Board of Directors at an important time for the Company. Anaphylm has the potential to change how patients treat severe allergic reactions, including anaphylaxis. I have spent my career preparing organizations for moments like this one, and I look forward to working with the Board and the management team as Aquestive prepares for its potential launch.”

About Richard Daly

Rich Daly is a life sciences executive with more than 30 years of leadership experience spanning large pharmaceutical companies, emerging biotechnology companies, and public company boards. He currently serves as President of Global Rare Disease at Angelini Pharma S.p.A. following Angelini’s acquisition of Catalyst Pharmaceuticals, Inc., where Mr. Daly served as President and Chief Executive Officer. At Catalyst, Mr. Daly served as President and Chief Executive Officer and oversaw the company’s commercial and business-development activities, including the U.S. launch of Agamree®.

Earlier in his career, Mr. Daly held senior commercial and operating roles at Takeda Pharmaceutical Company Limited, including Executive Vice President, Americas, where he led the company’s Americas business and directed the integration of TAP Pharmaceuticals, Inc. into Takeda, and at AstraZeneca, where as President of the U.S. Diabetes business he oversaw the launches of Farxiga® and Myalept®. He began his biopharmaceutical career at Abbott Laboratories. In biotechnology, Mr. Daly served as Chairman and Chief Executive Officer of Neuralstem, Inc., Chief Operating Officer of BeyondSpring Pharmaceuticals, Inc., Chief Operating Officer and a board member of Seed Therapeutics, Inc., and President of CARsgen Therapeutics Holdings Limited. He previously served on the boards of directors of Catalyst Pharmaceuticals, Inc., Opiant Pharmaceuticals, Inc., Neuralstem, Inc., and Synergy Pharmaceuticals, Inc., where he chaired the Nominating and Governance Committee and served on the Compensation Committee.

About Aquestive

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive’s AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward-Looking Statement

Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of Anaphylm™ (dibutepinephrine) sublingual film for the proposed indication of severe allergic reactions, including anaphylaxis through the U.S. Food and Drug Administration regulatory review and approval process and commercial launch; the potential benefits Anaphylm could bring to patients, and other statements that are not historical facts.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including delays to the timing, costs and success of its product development activities, clinical trials and regulatory applications, including relating to Anaphylm (dibutephinephrine) sublingual film, and other uncertainties affecting the Company described in the “Risk Factors” section and elsewhere in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company undertakes no obligation to update any forward-looking statement after the date of this press release, whether as a result of new information, future events or otherwise, except as required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

Investor inquiries:
astr partners
Brian Korb
brian.korb@astrpartners.com

MONTRÉAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V: FPC) (“Falco” or the “Corporation”) is pleased to announce the results of a third-party Socioeconomic Impact Study (the “Report”) conducted by KPMG LLP (“KPMG”) for the Corporation’s Horne 5 Project located in Rouyn-Noranda, Québec, Canada (the “Horne 5 Project” or the “Project”). The Report outlines the significant economic and labour opportunities of the Horne 5 Project, based on the Project’s updated feasibility study report filed on July 27, 2026, under the Corporation’s profile on SEDAR+ at www.sedarplus.ca (the “2026 Feasibility Study”).

The Report confirms that over the Project’s anticipated lifespan, its direct and indirect contribution to Gross Domestic Product (“GDP”) within the Québec economy at the provincial level is currently estimated at $8.8 billion. The complete Report is available on the Corporation’s website at www.falcores.com (in French only).

Luc Lessard, Falco’s President and CEO, stated: “KPMG’s analysis demonstrates the scale of Horne 5’s potential economic contribution to Québec, and particularly Abitibi-Témiscamingue. With an estimated $8.8 billion contribution to the Québec GDP, more than 22,800 direct and indirect jobs in person-years and approximately $5.1 billion in municipal, provincial and federal tax revenues over the Project’s life, Horne 5 has the potential to generate substantial and lasting economic benefits. Importantly, KPMG estimates that 82% of the value added generated in Québec would accrue to Abitibi-Témiscamingue, reinforcing the Project’s significance to the region.”

Key Highlights from KPMG’s Report (figures and timelines are estimates)

KPMG’s analysis considers approximately $12.1 billion of Project expenditures over 15 years, including pre-production investments, recurring operating costs, and site maintenance and reclamation expenses.

Economic Impact of the Horne 5 Project

Pre-Production & Construction Phase (4 Years)

• Provincial Impact (Québec): $914.4 million in GDP ($228.6 million per year), 4,318 jobs in person-years and $59.4 million in provincial tax revenue.
• Regional Impact (Abitibi-Témiscamingue): $644.6 million in GDP ($161.1 million per year), 2,075 jobs in person-years, and $3.5 million in local tax revenue.
• $32.7 million in federal tax revenue.

Operational and Closure Phases (15 Years)

• Provincial Impact: $7.9 billion in GDP ($524.5 million per year), 18,485 jobs in person-years, and $3.5 billion in provincial tax revenue ($233.6 million per year).
• Regional Impact: $6.5 billion in GDP ($435.8 million per year),11,808 jobs in person-years, and $37.5 million in local tax revenue.
• $1.4 billion in federal tax revenue ($95.6 million per year).

Overall, 82% of the direct and indirect added value generated by the Project is expected to accrue to the Abitibi-Témiscamingue region, which is expected to retain 61% of the jobs supported by the Project.

Additional Highlights from KPMG’s Report

• Workforce Development: The Horne 5 Project will support workforce training and skills development, with a focus on trades and technical roles.
• Local Community: Significant employment and business opportunities, in addition to infrastructure improvements.
• Environmental Sustainability: Falco is committed to minimizing the Project’s environmental footprint through the use of modern technologies, responsible water and tailings management, and the reuse of existing mining infrastructure wherever practicable.
• Supply Chain and Export Potential: The Project will strengthen provincial supply chain for critical minerals.
• Government Alignment: The Project supports Québec and Canada’s strategic priorities for critical minerals and responsible resource development, while contributing to domestic mineral supply and long-term economic growth.

About Falco

Falco is one of the largest mineral claim holders in the province of Québec, with an extensive portfolio of properties in the Abitibi-Témiscamingue greenstone belt. Falco holds rights to approximately 60,000 hectares of land in the Noranda Camp, which includes 13 former gold and base metal mine sites. Falco’s main asset is the Horne 5 Project located beneath the former Horne mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper. Osisko Gold Group Inc. is Falco’s largest shareholder, with a 16.0% interest in the Corporation.

For further information, please contact:

Luc Lessard
President and Chief Executive Officer and Director
514-261-3336
info@falcores.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are typically identified by words such as: “believe”, “envisions”, “estimates”, “assumes”, “evaluates”, “inferred”, “probability”, “planned”, “projected”, “ensure” “anticipates”, “contemplated”, “expected”, “anticipate” and similar expressions, or that events or conditions “would”, “will”, “can”, or may” occur. All statements that are not statements of historical fact are forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding the projections and assumptions of the Report, including, without limitation: expected direct and indirect Québec and regional GDP contribution from the Project; expected federal, provincial and local tax revenue; and economic assumptions and sensitivities and other operational and economic projections with respect to the Horne 5 Project as well as benefits of the Project for the community.

Although the Corporation believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. Consequently, the Corporation cautions investors that any forward-looking statements by the Corporation are not guarantees of future results or performance and that actual results may differ materially from those in forward-looking statements.

The forward-looking statements contained herein is subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements, including, without limitation: the effects of general economic conditions; changing foreign exchange rates; risks associated with exploration and project development; the calculation of mineral resources and reserves; risks related to fluctuations in metal prices; uncertainties related to raising sufficient financing to fund the planned work in a timely manner and on acceptable terms; changes in planned work arising from weather, logistical, technical or other factors; the possibility that results of work will not fulfill expectations and realize the perceived potential of the Corporation’s properties; risk of accidents, equipment breakdowns and labour disputes; access to project funding or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in the work program; title matters; government regulation; obtaining and receiving necessary licenses; the risk of environmental contamination or damage resulting from Falco’s operations, the risk that the conditions precedent to the ability to conduct dewatering or mining activities under the operating license and indemnity agreement (“OLIA”) dated January 23, 2024 between Falco and Glencore Canada Corporation (“Glencore”) may not be satisfied; the risk that Falco may not obtain the required financial assurances to be provided to Glencore, or the financing required to develop or operate the Horne 5 Project; the risk that the required permits and authorizations required from governmental authorities to develop and operate the Horne 5 Project may not be obtained on the terms contemplated or at all; the risk that the OLIA may be terminated in accordance with its terms in the event of default or certain other triggers relating to delays in the commencement of dewatering or mining activities; the risk that, once commenced, certain operations of the Horne 5 Project may have to be suspended, altered or modified pursuant to the conditions of the OLIA; the risk that Glencore may require modifications to Falco’s operations at the Horne 5 Project pursuant to the OLIA which would render the operations less profitable or not profitable (compared to expectations included in the 2026 Feasibility Study); the risk that Falco may incur significant losses and other obligations under its indemnities in favour of Glencore contemplated in the OLIA; and other risks and uncertainties including those described in the Corporation’s Management’s Discussion & Analysis for the three-month and nine-month period ended March 31, 2026, dated May 20, 2026 available at www.sedarplus.ca.

The forward-looking statements contained in this news release are based on the beliefs, estimates and opinions of Falco’s management on the date the statements are made. Although Falco has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation is under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.

Innovative design will future-proof the EVgo network as vehicle battery capabilities advance while focusing on features to enhance the customer experience

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) — EVgo Inc. (Nasdaq: EVGO) (“EVgo” or the “Company”), one of the nation’s largest public fast charging networks for electric vehicles (EVs), shared a preview of its next-generation charging system, capable of delivering up to 750kW of charging power.

Design, development, and testing for the Company’s new charger are being performed at EVgo’s Innovation Lab in El Segundo, California, with co-development support from longtime partner Delta Electronics. With this architecture, EVgo is one of the only American charging networks to design its own chargers.

“EVgo has served EV drivers for over 15 years, and our investment in our 750kW next-generation architecture future-proofs our network for current and future vehicles,” said Badar Khan, CEO of EVgo. “Charge rates seen on the EVgo network are increasing, up nearly 20% in the last two years. We expect that to continue, and our new architecture will help meet growing demand for high-power charging while delivering an industry-leading customer experience for EV drivers.”

At the heart of EVgo’s design is a focus on the EV driver experience, leveraging learnings from working with 1.8 million customer accounts and analyzing data from over 10 million sessions per year. Features include better cable maneuverability, a touchless payment interface, and advanced hardware and firmware to bolster reliability and streamline the charging experience. Each station will feature NACS connectors as part of EVgo’s overall strategy to double its addressable market by welcoming more NACS drivers to its customer base. This system is expected to charge the fastest charging vehicles in the U.S. market in around 10 minutes.¹

The new chargers will use dynamic power sharing, which is increasingly important as battery technology advances and charge rate variability widens across available vehicle models for consumers. This approach ensures each dispenser delivers the exact output each vehicle needs throughout a charging session, automatically adjusting energy distribution in real time. Drivers won’t have to worry about finding a certain power-level stall because every stall is the right one for their vehicle. Dynamic power sharing also supports grid stability through flexible energy allocation, routing power where it is needed most while smoothing demand spikes.

The final charger design is expected to be unveiled in 2027 as EVgo begins to deploy the new architecture. 

¹ Actual charging time will vary based on vehicle’s charging speed and settings, battery condition, ambient temperature, and initial state of charge. See our FAQs for recommended charging parameters and assumptions. 

About EVgo 

EVgo (NASDAQ: EVGO) is one of the nation’s largest and most highly utilized public fast charging providers. With more than 1,200 fast charging locations across 47 states, EVgo makes charging part of everyday life by partnering with leading businesses including retailers, grocery stores, rideshare operators and autonomous vehicle companies. EVgo is scaling nationwide, strategically deploying high-power chargers, including EVgo Superchargers, across the U.S. At its dedicated Innovation Lab, EVgo is developing its next-generation chargers, performing extensive interoperability testing and collaborating with leading automakers and industry partners to advance the EV charging industry and deliver a seamless charging experience.

Forward-Looking Statements 

This press release contains forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to: EVgo’s plans, projections, and expectations regarding its next-generation chargers; the capabilities and features of such chargers, including cable maneuverability, NACS, and hardware and firmware features and the impact they will have on reliability and customer experience; and the anticipated impact of such chargers on EVgo’s charging network, the expected timing of deployment, and benefits for EVgo’s customers. Forward-looking statements are based on EVgo’s management’s current assumptions, expectations, and beliefs and are not guarantees of future performance. These statements are subject to a number of risks, uncertainties, and assumptions, including those described under the heading “Risk Factors” and elsewhere in our most recent Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K filed with the Securities and Exchange Commission. In light of these risks, uncertainties, and assumptions, actual results could differ materially and adversely from those anticipated or implied by the forward-looking statements. You should not rely on forward-looking statements as predictors of future results. Any forward-looking statements in this release are based on the limited information currently available to EVgo as of the date hereof, which is subject to change, and EVgo does not undertake any obligation to update these statements, even if new information becomes available in the future.

Contacts    

For Investors:
investors@evgo.com     

For Media:
press@evgo.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/74bb6a65-ae35-489f-8994-de1870f44466

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million

Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin. The midpoint represents an increase of $55 million, or ~15%, over the previous guidance range of $350 to $370 million and implies nearly 60% annual growth in total revenue.

“Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. “Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues. In addition, lifileucel continues to advance across our registrational programs in new solid tumor indications, while continued manufacturing and operating efficiencies accelerate our progress toward profitability.”

Iovance most recently reported record second quarter 2026 total product revenue of $99.3 million, has grown its authorized treatment center (ATC) network to ~100 centers, and remains on track for expansion to at least 110 ATCs by year-end 2026.

Iovance expects to report third quarter 2026 financial results in early November 2026. This update completes the guidance review announced with the Company’s second quarter 2026 results.

About Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products; the acceptance by the market of our products and product candidates, if approved, and their potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product candidates; the risk regarding our ability to manufacture our therapies at our iCTC facility, including the risk that our ability to increase manufacturing capacity at our facility may adversely affect our commercial launch; the risks related to our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with regulatory authorities, may support registrational studies and subsequent approvals by regulatory authorities, including the risk that any of our planned registrational trials may not support approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of ATCs, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates.

CONTACTS 

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com 
650-260-7120 ext. 150

• Jurassic Battery Energy Storage System is Alberta’s largest battery energy storage facility, delivering 80 MW / 160 MWh of grid-balancing capacity
• Northland’s second storage project was delivered ahead of schedule and under budget with zero lost-time incidents
• 15-year offtake agreement covering 100% of capacity provides long-term contracted cash flows

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced that its 80 MW / 160 MWh Jurassic Battery Energy Storage System (BESS) has achieved commercial operations, bringing Alberta’s largest battery storage facility online and marking another milestone in Northland’s successful project delivery.

The Jurassic BESS facility was delivered ahead of schedule and under budget. The project was constructed with zero lost-time incidents across nearly 75,000 hours worked. The project is supported by a 15-year offtake agreement covering 100% of its capacity, providing long-term contracted cash flows.

“Achieving commercial operations at Jurassic BESS demonstrates Northland’s ability to consistently deliver energy infrastructure safely, efficiently, and as planned,” said Christine Healy, President and Chief Executive Officer of Northland Power. “Jurassic BESS highlights our exceptional project execution and multi-technology capabilities and operations across electricity generation and storage.”

ABOUT NORTHLAND POWER

Northland Power is a Canadian-headquartered global power producer delivering the electricity the world needs through offshore wind, onshore renewables, battery storage, and natural gas-fired generation. With offices in seven countries, Northland owns, in whole or in part, 3.6 GW of gross operating generating capacity, 2.4 GW under construction, and an approximately 8 GW development pipeline, reflecting nearly four decades of experience delivering large-scale energy infrastructure. 

Publicly traded since 1997, Northland’s Common Shares, and Series 1 and Series 2 Preferred Shares trade on the Toronto Stock Exchange under the symbols NPI, NPI.PR.A and NPI.PR.B, respectively. 

For further information, please contact:

Alison Holditch, Head of Investor Relations
+ 1 (416) 989-8734
investorrelations@northlandpower.com

Victor Gravili, Vice President of Corporate Affairs
+1 (416) 895-5433
communications@northlandpower.com

FORWARD LOOKING INFORMATION

This news release contains statements that constitute forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that are provided for the purpose of presenting information about management’s current expectations and plans. Readers are cautioned that such statements may not be appropriate for other purposes. Northland’s actual results could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, the events anticipated by the forward-looking statements may or may not transpire or occur. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as “anticipates”, “expects,” “believes,” or negative versions thereof and other similar expressions or future or conditional verbs such as “may,” “will,” “should,” “would” and “could.” These statements may include, without limitation, statements regarding Northland’s expectations for the operating capacity of the Project and the size of Northland’s development pipeline, all of which may differ from the expectations stated herein. These statements are based upon certain material factors or assumptions that were applied in developing the forward-looking statements, including the provisions of contracts to which Northland or a subsidiary is a party, as well as other factors, estimates, and assumptions that are believed to be appropriate in the circumstances. Although these forward-looking statements are based upon management’s current reasonable expectations and assumptions, they are subject to numerous risks and uncertainties. Some of the factors include, but are not limited to, those described in the “Risks Factors” section of Northland’s Management’s Discussion and Analysis and Annual Information Form for the year ended December 31, 2025, which can be found at www.sedarplus.ca under Northland’s profile and on Northland’s website at northlandpower.com. Northland has attempted to identify important factors that could cause actual results to materially differ from current expectations, however, there may be other factors that cause actual results to differ materially from such expectations. Northland’s actual results could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, and Northland cautions you not to place undue reliance upon any such forward-looking statements.

The forward-looking statements contained in this release are, unless otherwise indicated, stated as of the date hereof and are based on assumptions that were considered reasonable as of the date hereof. Other than as specifically required by law, Northland undertakes no obligation to update any forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (“GoldHaven” or the “Company”) is pleased to highlight that, while current drilling is focused on the Kuhn target, GoldHaven’s amended Mines Act Permit provides the Company with significant flexibility to systematically evaluate multiple high-priority exploration areas across the broader Magno Project.

The permit authorizes up to 93 ground-based drill pads across seven work zones, four staging areas, modifications to up to 45 kilometres of existing access, and additional exploration trail construction within the approved work program.

Highlights

• 93 permitted drill pads across seven work zones provide flexibility to test multiple targets across Magno.
• 2026 drilling is underway at Kuhn, targeting tungsten-bearing skarn mineralization.
• D Zone / Magno hosts high-grade historical silver-lead-zinc mineralization, including 7.6 metres grading 240 g/t Ag, 4.73% Pb and 4.74% Zn.
• The broader project hosts tungsten, silver, lead, zinc, copper and critical-mineral potential within a large intrusion-related system.
• Permitted targets extend beyond Kuhn to include Dead Goat, D Zone / Magno, Lamb Mountain, Contact and Lang Creek.

Rob Birmingham, President and CEO of GoldHaven, commented:

“Kuhn remains a key focus of our 2026 drill program, but it is also one part of a much broader mineralized system. With 93 permitted drill pads across seven work zones, we have the flexibility to evaluate multiple targets across a large project footprint. As drilling advances at Kuhn, our technical team is also evaluating D Zone and other priority areas across Magno to determine how best to allocate the remainder of our 2026 drill program.”

A Multi-Target Exploration Opportunity

GoldHaven’s permitted exploration footprint encompasses several areas of geological interest across Magno and provides the Company with multiple opportunities to evaluate different mineralization styles within the broader property-scale system.

Figure 1: Magno Project – 93 Permitted Drill Pads Across Seven Multi-Target Work Zones

Kuhn and Dead Goat

The current focus of GoldHaven’s 2026 drill campaign and the Company’s principal tungsten-skarn target area. Historical and modern work has identified tungsten-bearing skarn developed within favourable carbonate stratigraphy adjacent to intrusive rocks.

At Kuhn, two principal skarn horizons, the Lower and Upper 3a, have been traced at surface for approximately 640 metres and 206 metres, respectively, with geological mapping indicating potential strike extensions of up to approximately 2 kilometres. The skarns are characterized by diopside-garnet assemblages with scheelite, pyrrhotite and locally molybdenum and base-metal mineralization. Similar tungsten-bearing skarn occurs at Dead Goat, where mineralization has been mapped over a surface expression of up to approximately 200 metres.

D Zone / Magno Area

A high-priority polymetallic target area characterized by silver-lead-zinc mineralization hosted within carbonate rocks of the Lower Cambrian Atan Group. Historical and recent work has identified structurally controlled skarn and carbonate-replacement-style mineralization occurring as bedding-parallel “manto” bodies and crosscutting “chimney”-style zones.

Mineralization includes galena, sphalerite, magnetite and locally massive sulphides, providing the Company with a distinctly different target style from the tungsten-focused Kuhn area.

Historical drilling at the D Zone included a reported interval of 7.6 metres grading 240 g/t silver, 4.73% lead and 4.74% zinc. This historical result predates NI 43-101 and has not been independently verified by a Qualified Person for GoldHaven.

More recent exploration has confirmed strong silver-lead-zinc mineralization across the broader Magno and D Zone trend, including silver values exceeding 2,000 ppm in structurally controlled skarn mineralization.

Lamb Mountain

A permitted exploration area located north of the central Magno target area and positioned within the broader intrusive and mineralized system being evaluated by GoldHaven. Property-wide geochemical work has identified elevated high-temperature pathfinder elements in the broader area south of Lamb Mountain, including anomalous bismuth, which forms part of the dataset being used to trace structural fluid pathways and vector toward potential intrusive sources.

Contact Area

A centrally located permitted exploration area positioned within the broader Magno intrusive and carbonate-contact environment. The Magno Project covers the contact between Cretaceous-aged intrusive rocks and carbonate-rich sedimentary rocks of the Cassiar Terrane, a geological relationship interpreted to control much of the property’s skarn and carbonate-replacement mineralization. The Contact Area provides an opportunity to evaluate additional sections of this favourable intrusive-carbonate interface.

Lang Creek

A permitted exploration area in the southern portion of the Magno Project, located near Highway 37 and forming part of GoldHaven’s broader strategy to evaluate mineralization across the entire property. Its location provides an additional opportunity to evaluate prospective geology along the southern extent of the Magno system while benefiting from nearby road access. The Company intends to integrate geological mapping, historical information, geochemistry and geophysical data when prioritizing future drilling across Lang Creek and other permitted target areas.

The approved work program provides access to the Kuhn and Dead Goat, Granite D / Magno, Lamb Mountain, Contact and Lang Creek areas, allowing GoldHaven to progressively evaluate multiple target styles across the broader Magno mineral system.

Property-Scale Geological Framework

GoldHaven’s recent work has helped define a broader property-scale mineral zonation model at Magno. Integrated geological mapping, sampling and geochemical analysis indicate an intrusion-related system with copper-gold-silver mineralization in more proximal settings, silver-lead-zinc mineralization in intermediate zones, and tungsten-skarn and additional replacement-style mineralization elsewhere across the property.

Recent work has identified copper values of up to 6,660 ppm at Magno, elevated copper within intrusive rocks, tungsten mineralization at Kuhn and Dead Goat, and strong bismuth and tellurium anomalies interpreted as high-temperature pathfinder elements and indicators of structural fluid pathways. Elevated indium associated with zinc mineralization further reinforces the project’s broader critical-mineral potential.

Building Beyond Kuhn

GoldHaven is currently evaluating the sequencing and prioritization of additional targets as drilling progresses at Kuhn. Geological observations, historical exploration data, surface geochemistry and geophysical information are being integrated to determine where additional drill metres can generate the greatest exploration value.

The Company expects to provide further updates regarding target prioritization and drilling plans as the 2026 program progresses.

Historical Results and Estimates

Certain historical exploration results and estimates referenced in this news release were completed prior to the implementation of NI 43-101 and have not been independently verified by a Qualified Person for GoldHaven. These historical results should not be relied upon as current mineral resources or reserves. The Company considers the historical information relevant as a guide to ongoing exploration and intends to continue evaluating and verifying these areas through modern exploration methods.

Qualified Person

The technical and scientific information contained in this news release has been reviewed and approved by Raymond Wladichuk, P.Geo., who is a non-independent Qualified Person as defined under NI 43-101 and a consultant of the Company.

About GoldHaven Resources Corp.

GoldHaven Resources Corp. is a Canadian junior exploration company focused on advancing highly prospective mineral projects in North and South America. The Company’s flagship asset is the district-scale Magno Project in the Cassiar District of northern British Columbia. GoldHaven also owns the Three Guardsmen copper-gold project in British Columbia and the Copeçal Gold Project in Mato Grosso, Brazil. In addition, the Company holds a portfolio of critical-mineral projects in Brazil.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE – Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward-Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained demand and prices for precious metals, base metals and critical minerals, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the inability of the Company to enter into definitive agreements in respect of possible Letters of Intent, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis as filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

• The amended Mines Act Permit providing flexibility to systematically evaluate multiple high-priority exploration areas across the Magno Project;
• The 2026 drill program at Kuhn testing tungsten-bearing skarn mineralization;
• Potential strike extensions of the Lower and Upper 3a skarn horizons at Kuhn of up to approximately 2 kilometres;
• Evaluation of D Zone and other priority areas to determine allocation of the remainder of the 2026 drill program;
• The Magno Project hosting tungsten, silver, lead, zinc, copper and critical-mineral potential within a large intrusion-related system;
• Progressive evaluation of multiple target styles across the Kuhn and Dead Goat, D Zone / Magno, Lamb Mountain, Contact and Lang Creek areas;
• Integration of geological mapping, historical data, geochemistry and geophysics to prioritize future drilling at Lang Creek and other permitted targets;
• Sequencing and prioritization of additional targets as drilling progresses at Kuhn, and additional drill metres generating the greatest exploration value;
• Elevated indium associated with zinc mineralization reinforcing the project’s broader critical-mineral potential;
• Further updates regarding target prioritization and drilling plans as the 2026 program progresses; and
• Continued evaluation and verification of historical results through modern exploration methods.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ffa73a54-872d-45e1-bfff-c1d4ef531a1c